Focused On-demand Library for Exosome complex component RRP46

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NQT4

UPID:

EXOS5_HUMAN

Alternative names:

Chronic myelogenous leukemia tumor antigen 28; Exosome component 5; Ribosomal RNA-processing protein 46; p12B

Alternative UPACC:

Q9NQT4; Q32Q81; Q8NG16; Q96I89

Background:

Exosome complex component RRP46, also known as Exosome component 5 or Chronic myelogenous leukemia tumor antigen 28, plays a crucial role in RNA processing and degradation. It is a non-catalytic component of the RNA exosome complex, involved in the maturation of stable RNA species, elimination of RNA processing by-products, and degradation of unstable mRNAs. This protein's activity is essential in both the nucleus and the cytoplasm for maintaining RNA homeostasis.

Therapeutic significance:

The involvement of Exosome complex component RRP46 in cerebellar ataxia, brain abnormalities, and cardiac conduction defects highlights its potential as a therapeutic target. Understanding the role of Exosome complex component RRP46 could open doors to potential therapeutic strategies for these conditions.